V Torri
Overview
Explore the profile of V Torri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
4356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrone O, Paccagnella M, Abbona A, Ruatta F, Vanella P, Denaro N, et al.
ESMO Open
. 2024 Dec;
9(11):103983.
PMID: 39617533
No abstract available.
2.
Garrone O, Paccagnella M, Abbona A, Ruatta F, Vanella P, Denaro N, et al.
ESMO Open
. 2024 Aug;
9(8):103665.
PMID: 39121813
Background: Physical activity (PA) reduces the risk of developing breast cancer (BC) and mortality rate in BC patients starting PA after diagnosis. Immunomodulation is considered responsible for these effects. However,...
3.
Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, et al.
Ann Oncol
. 2024 Jun;
35(9):817-826.
PMID: 38857846
Background: Thymic carcinoma (TC) is a rare tumor with aggressive behavior. Chemotherapy with carboplatin plus paclitaxel represents the treatment of choice for advanced disease. Antiangiogenic drugs, including ramucirumab, have shown...
4.
Nader-Marta G, Monteforte M, Agostinetto E, Cinquini M, Martins-Branco D, Langouo M, et al.
ESMO Open
. 2024 Mar;
9(3):102390.
PMID: 38460249
Background: The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess...
5.
Magugliani G, Marranconi M, Liosi G, Locatelli F, Gambirasio A, Trombetta L, et al.
Phys Med
. 2023 Oct;
114:103158.
PMID: 37806152
Purpose: Complex stereotactic radiotherapy treatment plans require prior verification. A gel dosimetry system was developed and tested to serve as a high-resolution 3D dosimeter for Quality Assurance (QA) purposes. Materials...
6.
Trevisan B, Pepe F, Vallini I, Montagna E, Amoroso D, Berardi R, et al.
Sci Rep
. 2023 Jul;
13(1):12255.
PMID: 37507480
Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and...
7.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco M, et al.
ESMO Open
. 2023 Feb;
8(1):100777.
PMID: 36731325
Background: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative...
8.
Di Giorgio A, Gerardi C, Abatini C, Melotti G, Bonavina L, Torri V, et al.
Trials
. 2022 Dec;
23(1):969.
PMID: 36457115
Introduction: At the time of diagnosis, 15-20% of gastric carcinomas are in stage T4 or T4b. Furthermore, 5-20% of patients undergoing potentially curative surgery suffer from synchronous or metachronous peritoneal...
9.
Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, et al.
ESMO Open
. 2022 Dec;
7(6):100645.
PMID: 36455507
Background: The PEOPLE trial aimed to identify new immune biomarkers in negative and low programmed death-ligand 1 (PD-L1) (0%-49%) advanced non-small-cell lung cancer (aNSCLC) patients treated with first-line pembrolizumab. Here...
10.
Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, et al.
Ann Oncol
. 2022 Jan;
33(4):454.
PMID: 35086737
No abstract available.